1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > US Cancer Vaccine Market Outlook 2022

US Cancer Vaccine Market Outlook 2022

  • July 2016
  • -
  • RNCOS
  • -
  • 135 pages

Cancer is one of the major health issues faced by the countries across the globe. The researchers are engaged in developing various drugs for the prevention and treatment of the disease. Cancer vaccine is one such example. Since their inception, cancer vaccines were considered as high potential method for preventing and treating cancer. Till date, the vaccines have not been able to achieve the expected sales due to high cost and negative results in clinical trials. However, with launch of new cancer vaccines, such as Imlygic by Amgen; and increasing awareness of people regarding these vaccines, the market is expected to grow.

The US is largest market for cancer vaccines. The growth of the US cancer vaccine market is driven by increasing cancer incidence in the country, rising awareness, and strong pipeline. The “US Cancer Vaccine Market Outlook 2022” report provides detailed analysis of the market. This report covers the present scenario and the growth prospects of US cancer vaccine market for the period 2015-2022. It also covers the drivers, restraints hampering the growth of the market, and future opportunities. Moreover, the report provides the global sales of various cancer vaccines from 2013-2015.

On the basis of type of cancer for which the vaccine is targeted, the market has been segmented into three types, namely, liver cancer, HPV related cancer, and others. Currently, HPV related cancer vaccines occupy the largest share in the US market.

On the basis of type of vaccine, the market has been further sub-divided into prophylactic vaccines and therapeutic vaccines. The prophylactic vaccines accounts for the largest share in 2016. The large share of this market is attributed to various vaccination programs organized by the US government for prevention against HPV and hepatitis. The therapeutic vaccines are expected to witness high growth in coming years due to strong pipeline. Amongst the various research studies, a vaccine for lung cancer can be expected to come up soon with promising candidates, such as TV4010 and GV1001, having entered phase 3 trials.

The report also provides market share analysis by key players. Merck and GSK are expected to continue to be undisputed market leaders in the cancer vaccine market. Furthermore, the report also covers the FDA's vaccine approval procedure, and its guidance to the industry for developing therapeutic cancer vaccines. Additionally, the report also enlists the pipeline of cancer vaccines which are in various clinical trial phases. The patent analysis of products in US has also been added in the report on the basis of year of grant, type of patent, and assignee of the patent.

The last section of the report discusses about the key players in the US cancer vaccine market. A brief business overview and financial information about each of these players has been provided in the report. Moreover, this report will help the reader to gain crucial insight into the key players’ performances and strategies for growth. Conclusively, the research will prove to be a useful resource for all debut makers in US cancer vaccine industry and potential investors.

Table Of Contents

US Cancer Vaccine Market Outlook 2022
1. Analyst View
2. Research Methodology
3. Cancer Statistics by Demographics
3.1 Prevalence, Incidences and Mortality
3.2 Leading States by Incidences
3.3 Leading Cancers by Incidences
3.3.1 Male Cancer Incidences
3.3.2 Female Cancer Incidences
3.3.3 Children Cancer Incidences
4. Market Dynamics
4.1 Drivers
4.1.1 Rising Cancer Incidences
4.1.2 Ability to Reduce Healthcare Expenditure
4.1.3 Rising Awareness
4.1.4 Patient Assistance Programs
4.1.5 Government Initiatives
4.1.6 Strong Pipeline
4.1.7 Technological Advancements
4.2 Restraints
4.2.1 High Cost of Cancer Vaccines
4.2.2 Side Effects of Cancer Vaccines
4.2.3 Vaccine Supply Shortages
4.2.4 Insurance Issues Related to Cancer Vaccination
4.3 Opportunities
4.3.1 Therapeutic Cancer Vaccines
4.3.2 Adjuvant Cancer Vaccines
5. Cancer Vaccines Market Outlook
5.1 Key Product Analysis
5.1.1 Provenge
5.1.1.1 Market Analysis
5.1.2 T-Vec/Imlygic
5.1.2.1 Market Analysis
5.1.3 HPV Vaccine
5.1.3.1 Gardasil
5.1.3.1.1 Market Analysis
5.1.3.2 Cervarix
5.1.3.2.1 Market Analysis
5.1.4 HBV Vaccines
5.1.4.1 Engerix-B
5.1.4.1.1 Market Analysis
5.1.4.2 Recombivax HB
5.1.4.2.1 Market Analysis
5.1.4.3 Pediarix/ Infanrix
5.1.4.3.1 Market Analysis
6. Cancer Vaccines Market by Cancer Type
7. Cancer Vaccine Market by Application
8. Potential Cancer Vaccine Candidates: An Opportunity Assessment
8.1 Prophylactic Vaccine
8.2 Therapeutic Vaccine
8.2.1 Prostate Cancer
8.2.2 Breast Cancer
8.2.3 Lung Cancer
8.2.4 Colorectal Cancer
9. US Patent Analysis
9.1 Patents by Year
9.2 Patents by Category
9.2.1 Utility Patents
9.2.2 Design Patents
9.2.3 Plant Patents
9.3 Patents by Company
9.4 Patents by Assignee Type
9.4.1 By Assignee Name
9.4.2 By Assignee State
10. Regulatory Environment
10.1 Vaccine Approval Process
10.2 FDA Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines
10.2.1 Considerations for both Early and Late Phase Clinical Trials
10.2.1.1 Patient Population
10.2.1.2 Monitoring the Immune Response
10.2.1.3 Biomarkers as Evidence of Efficacy
10.2.1.4 Adjuvants Used to Stimulate Immune Response
10.2.1.5 Multi-antigen Vaccines
10.2.1.6 Disease Progression/Recurrence Immediately or Shortly after the Initial Administration of Cancer Vaccines
10.2.1.7 Concomitant and Subsequent Therapies
10.2.2 Considerations for Early Phase Clinical Trials
10.2.2.1 Starting Dose and Dosing Schedule
10.2.2.2 Booster and Maintenance Therapy
10.2.2.3 Dose Escalation
10.2.2.4 Single-arm versus Randomized Phase-2 Trials in Early Development
10.2.3 Considerations for Late Phase Clinical Trials
10.2.3.1 Safety Profile from Early Phase Clinical Trials
10.2.3.2 Endpoints
10.2.3.3 Statistical Issues
10.2.3.4 Control Issues
10.2.3.5 Delayed Vaccine Effect
10.2.3.6 Autologous Vaccine Trials
10.2.3.7 Accelerated Approval Regulations
11. Competitive Landscape
12. Company Profiles
12.1 Merck and Co.
12.2 GlaxoSmithKline plc
12.3 Dendreon (A Subsidiary of Valeant Pharmaceuticals)
12.4 Amgen Inc.

List of Figures:

Figure 3-1: Cancer Incidences (Million), 2015-2022
Figure 3-2: Cancer Mortality (Million), 2015-2022
Figure 3-3: Incidences by Type of Cancer (%), 2016
Figure 3-4: States with Highest Cancer Incidences, 2015
Figure 5-1: Share of US in Global Cancer Vaccine Market (%), 2016
Figure 5-2: US - Cancer Vaccine Market by Product Type (%), 2016
Figure 5-3: Global - Provenge Market (Million US$), 2013-2015
Figure 5-4: Share of US in Global Imlygic Sales (%), 2015
Figure 5-5: Global - Gardasil Market (Million US$), 2013-2015
Figure 5-6: US - Gardasil Market (Million US$), 2013-2015
Figure 5-7: Share of US in Global Gardasil Sales (%), 2015
Figure 5-8: Global - Cervarix Market (Million US$), 2013-2015
Figure 5-9: US - Cervarix Market (Million US$), 2013-2015
Figure 5-10: Share of US in Global Cervarix Sales (%), 2015
Figure 5-11: Global - Engerix-B Market (Million US$), 2013-2015
Figure 5-12: US - Engerix-B Market (Million US$), 2013-2015
Figure 5-13: Share of US in Global Engerix-B Sales (%), 2015
Figure 5-14: Global - Recombivax HB Market (Million US$), 2013-2015
Figure 5-15: US - Recombivax HB Market (Million US$), 2013-2015
Figure 5-16: Share of US in Global Recombivax HB Sales (%), 2015
Figure 5-17: Global - Pediarix/Infanrix Market (Million US$), 2013-2015
Figure 5-18: US - Pediarix/ Infanrix Market (Million US$), 2013-2015
Figure 5-19: Share of US in Global Pediarix/Infanrix Sales (%), 2015
Figure 6-1: US - Cancer Vaccine Market by Cancer Type (%), 2016
Figure 6-2: US - Cancer Vaccine Market for Liver Cancer (Million US$), 2015-2022
Figure 6-3: US - Cancer Vaccine Market for HPV Related Cancer (Million US$), 2015-2022
Figure 6-4: US - Cancer Vaccine Market for Other Cancers (Million US$), 2015-2022
Figure 7-1: US - Cancer Vaccine Market by Application (%), 2016
Figure 7-2: US - Cancer Vaccine Market for Therapeutic Vaccines (Million US$), 2015-2022
Figure 7-3: US - Cancer Vaccine Market for Prophylactic Vaccines (Million US$), 2015-2022
Figure 8-1: Prophylactic Cancer Vaccines in Clinical Trials by Cancer Site (%), 2016
Figure 8-2: Prophylactic Cancer Vaccines in Clinical Trials by Phases (%), 2016
Figure 8-3: Therapeutic Cancer Vaccines in Clinical Trials by Cancer Site (%), 2016
Figure 8-4: Therapeutic Cancer Vaccines in Clinical Trials by Phases (%), 2016
Figure 8-5: Cancer Vaccines in Clinical Trials by Application (%), 2016
Figure 11-1: US - Share of Major Players in Cancer Vaccine Market (%), 2015
Figure 12-1: Merck and Co. - Breakup of Revenue by Segment (%), 2015
Figure 12-2: GlaxoSmithKline - Breakup of Revenue by Segment (%), 2015
Figure 12-3: Valeant Pharmaceuticals International, Inc. - Breakup of Revenue by Segment (%), 2015

List of Tables:

Table 3-1: Top 10 Cancer Incidences in Males (2015)
Table 3-2: Top 10 Cancer Incidences in Females (2015)
Table 3-3: Top 10 Cancer Incidences in Children (Ages 0-14), (2015)
Table 4-1: US - Cancer Incidences (Million), 2015 and 2020
Table 5-1: Global - Cancer Vaccine Market (Million US$), 2015-2022
Table 5-2: US - Cancer Vaccine Market (Million US$), 2015-2022
Table 8-1: Cancers with High Linkage to Virus and Bacteria
Table 8-2: Prophylactic Cancer Vaccines in Clinical Trials
Table 8-3: Therapeutic Cancer Vaccines in Clinical Trials
Table 8-4: Prostate Cancer Therapeutic Vaccines in Clinical Trials
Table 8-5: Breast Cancer Therapeutic Vaccines in Clinical Trials
Table 8-6: Lung Cancer Therapeutic Vaccines in Clinical Trials
Table 8-7: Colorectal Cancer Therapeutic Vaccines in Clinical Trials
Table 12-1: Merck and Co. - Key Financials (Million US$), 2013-2015
Table 12-2: Merck - Product Portfolio
Table 12-3: Merck - Cancer Vaccines in Pipeline
Table 12-4: GlaxoSmithKline - Key Financials (Million US$), 2013-2015
Table 12-5: GlaxoSmithKline - Product Portfolio
Table 12-6: GlaxoSmithKline - Cancer Vaccines in Pipeline
Table 12-7: Valeant Pharmaceuticals International, Inc. - Key Financials (Million US$), 2013-2015
Table 12-8: Dendreon - Product Portfolio
Table 12-9: Amgen Inc. - Key Financials (Million US$), 2013-2015
Table 12-10: Amgen Inc. - Product Portfolio

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Cancer Vaccines: Technologies and Global Markets

Cancer Vaccines: Technologies and Global Markets

  • $ 6650
  • Industry report
  • November 2016
  • by BCC Research

This cancer vaccines report by BCC Research explores present and future strategies within the market which includes prophylactic vaccines and therapeutic vaccines. Use this report to: - Analyze the global ...

Veterinary Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Veterinary Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • August 2016
  • by Transparency Market Research

Veterinary vaccines are extensively used in the prevention of life-threatening animal diseases. This report on the global veterinary vaccines market analyzes the current and future prospects of the market. ...

Human Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Human Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • October 2016
  • by Transparency Market Research

Human Vaccines Market: Scope and Methodology This report provides in-depth region wise and country wise analysis of the human vaccines market. Stakeholders of this report include manufacturers of human ...

Global Veterinary Vaccines Market

October 2016 $ 4250

Download Unlimited Documents from Trusted Public Sources

The future of the Vaccine Industry in the UK

  • December 2016
    2 pages
  • Vaccine  

    Infectious Dise...  

  • United Kingdom  

View report >

Vaccine Industry in Canada

  • December 2016
    6 pages
  • Vaccine  

  • Canada  

View report >

Influenza Statistics in the US

  • November 2016
    7 pages
  • Influenza  

    Influenza Vacci...  

    Vaccine  

  • United States  

View report >

Global Therapy Market

12 days ago

Global Vaccine Supply

18 days ago

Related Market Segments :

Vaccine
Cancer Vaccine

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.